Instituto Oftalmológico Fernández-Vega, Avda. Dres. Fernández-Vega, 34, 33012 Oviedo, Spain.
Instituto Universitario Fernández-Vega (Fundación de Investigación Oftalmológica, Universidad de Oviedo), 33012 Oviedo, Spain.
Nutrients. 2020 Mar 9;12(3):723. doi: 10.3390/nu12030723.
Nutritional supplementation with antioxidants and vitamins is widely recommended in the treatment of vascular disorders affecting the retina, although there is insufficient evidence on its effectiveness. The vitamin-like compound coenzyme Q10 (CoQ10) is a nutritional supplement of current interest to treat neurodegenerative diseases. Here, we report a retrospective clinical case series study of 48 patients diagnosed with retinal vascular diseases, including non-arteritic ischemic optic neuropathy (NAION), retinal artery occlusion (RAO), and homonymous hemianopia or quadrantanopia following stroke, treated with oral supplementation with CoQ10 (100 mg per day) and vitamins. Patient follow-up was performed using the Humphrey field analyzer and 30-2 testing algorithm to determine the visual field index (VFI) and progression rates. All treated patients showed positive VFI progression rates per year: +11.5 ± 15% for NAION patients ( = 18), +22 ± 17% for RAO patients ( = 7), +9.3 ± 10.5% for hemianopia/quadrantanopia patients ( = 10), and +11 ± 21% for patients with other conditions ( = 13). The interruption of CoQ10 supplementation in one patient resulted in a pronounced decrease of the VFI, which was partially recovered when treatment was restored. This study supports the role of CoQ10 as a nutritional therapeutic agent for vascular diseases affecting the retina. Owing to decreased VFI after interruption of CoQ10, its beneficial effects may be reversible.
抗氧化剂和维生素的营养补充广泛应用于治疗影响视网膜的血管疾病,尽管其疗效证据不足。类维生素化合物辅酶 Q10(CoQ10)是一种目前用于治疗神经退行性疾病的营养补充剂。在此,我们报告了一项回顾性临床病例系列研究,该研究纳入了 48 例诊断为视网膜血管疾病的患者,包括非动脉炎性缺血性视神经病变(NAION)、视网膜动脉阻塞(RAO)和卒中后同侧偏盲或象限盲,这些患者接受了 CoQ10(每天 100 毫克)和维生素的口服补充治疗。使用 Humphrey 视野分析仪和 30-2 测试算法对患者进行随访,以确定视野指数(VFI)和进展率。所有接受治疗的患者均显示出每年 VFI 的积极进展率:NAION 患者为+11.5±15%( = 18),RAO 患者为+22±17%( = 7),偏盲/象限盲患者为+9.3±10.5%( = 10),其他疾病患者为+11±21%( = 13)。一位患者中断 CoQ10 补充后 VFI 明显下降,当恢复治疗时部分恢复。这项研究支持 CoQ10 作为一种营养治疗剂,用于治疗影响视网膜的血管疾病。由于 CoQ10 中断后 VFI 降低,其有益作用可能是可逆的。